1. Home /
    2. Altai Protocol Library /
  2. New Indication: Lorlatinib for first-line ALK-positive NSCLC

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Lorlatinib for first-line ALK-positive NSCLC

New Indication: Lorlatinib for first-line ALK-positive NSCLC
Study:
  • Randomized phase III trial (CROWN)
  • Locally advanced or metastatic ALK-positive NSCLC
  • Lorlatinib 100 mg daily (n=149) vs. crizotinib 250 mg BID (n=147)
Efficacy:
  • ORR: 76% vs. 58% (OR: 2.25 [1.35-3.89])
  • PFS @ 1yr: 78% vs. 39% (HR: 0.28 [0.19-0.41])
  • Intracranial response: 66% vs. 20% (OR: 8.41 [2.59-27.23])
Safety:
  • Grade >=3 AEs: hypercholesterolemia (16% vs. 0%), hypertriglyceridemia (20% vs. 0%), weight gain (17% vs. 2%), hypertension (10% vs. 0%), cognitive effects (2% vs. 0%)

N Engl J Med 2020;383:2018-29.

Shaw AT, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

https://doi.org/10.1056/NEJMoa2027187

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More